Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders

Angelo Antonini, Laura Bernardi, Daniela Calandrella, Francesca Mancini, Mauro Plebani

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Rotigotine (Neupro®) is a non-ergolinic dopamine agonist available as a transdermal patch that can be applied once daily. To date, it is approved as monotherapy for the treatment of early Parkinson's disease (PD), and as adjunctive therapy to levodopa in the treatment of PD, including the advanced stage of the disease, when the efficacy of levodopa is reduced or becomes inconsistent and there are .uctuations in the therapeutic effect (end-dose, 'ON-OFF' phenomenon). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption is not needed, constant drug delivery, and ease of use. This review provides an overview of several aspects of the use of the rotigotine transdermal patch, including the important issue of the management of sleep disorders in advanced PD patients, as well as the chemistry, preclinical and clinical pharmacology, efficacy, safety and tolerability of the drug. Furthermore, the rationale for the treatment of PD with the rotigotine transdermal patch is discussed, focusing in particular on the related sleep disorders.

Original languageEnglish
Pages (from-to)21-25
Number of pages5
JournalFunctional Neurology
Volume25
Issue number1
Publication statusPublished - Jan 2010

Fingerprint

Transdermal Patch
Parkinson Disease
Levodopa
Clinical Pharmacology
Dopamine Agonists
Intestinal Absorption
Therapeutic Uses
Therapeutics
Pharmaceutical Preparations
N 0437
Sleep Wake Disorders
Safety

Keywords

  • Parkinson's disease
  • Quality of life
  • Rotigotine
  • Sleep

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. / Antonini, Angelo; Bernardi, Laura; Calandrella, Daniela; Mancini, Francesca; Plebani, Mauro.

In: Functional Neurology, Vol. 25, No. 1, 01.2010, p. 21-25.

Research output: Contribution to journalArticle

Antonini, A, Bernardi, L, Calandrella, D, Mancini, F & Plebani, M 2010, 'Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders', Functional Neurology, vol. 25, no. 1, pp. 21-25.
Antonini, Angelo ; Bernardi, Laura ; Calandrella, Daniela ; Mancini, Francesca ; Plebani, Mauro. / Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. In: Functional Neurology. 2010 ; Vol. 25, No. 1. pp. 21-25.
@article{5750d4cb335446dc8c86a2bfe9169eef,
title = "Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders",
abstract = "Rotigotine (Neupro{\circledR}) is a non-ergolinic dopamine agonist available as a transdermal patch that can be applied once daily. To date, it is approved as monotherapy for the treatment of early Parkinson's disease (PD), and as adjunctive therapy to levodopa in the treatment of PD, including the advanced stage of the disease, when the efficacy of levodopa is reduced or becomes inconsistent and there are .uctuations in the therapeutic effect (end-dose, 'ON-OFF' phenomenon). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption is not needed, constant drug delivery, and ease of use. This review provides an overview of several aspects of the use of the rotigotine transdermal patch, including the important issue of the management of sleep disorders in advanced PD patients, as well as the chemistry, preclinical and clinical pharmacology, efficacy, safety and tolerability of the drug. Furthermore, the rationale for the treatment of PD with the rotigotine transdermal patch is discussed, focusing in particular on the related sleep disorders.",
keywords = "Parkinson's disease, Quality of life, Rotigotine, Sleep",
author = "Angelo Antonini and Laura Bernardi and Daniela Calandrella and Francesca Mancini and Mauro Plebani",
year = "2010",
month = "1",
language = "English",
volume = "25",
pages = "21--25",
journal = "Functional Neurology",
issn = "0393-5264",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "1",

}

TY - JOUR

T1 - Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders

AU - Antonini, Angelo

AU - Bernardi, Laura

AU - Calandrella, Daniela

AU - Mancini, Francesca

AU - Plebani, Mauro

PY - 2010/1

Y1 - 2010/1

N2 - Rotigotine (Neupro®) is a non-ergolinic dopamine agonist available as a transdermal patch that can be applied once daily. To date, it is approved as monotherapy for the treatment of early Parkinson's disease (PD), and as adjunctive therapy to levodopa in the treatment of PD, including the advanced stage of the disease, when the efficacy of levodopa is reduced or becomes inconsistent and there are .uctuations in the therapeutic effect (end-dose, 'ON-OFF' phenomenon). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption is not needed, constant drug delivery, and ease of use. This review provides an overview of several aspects of the use of the rotigotine transdermal patch, including the important issue of the management of sleep disorders in advanced PD patients, as well as the chemistry, preclinical and clinical pharmacology, efficacy, safety and tolerability of the drug. Furthermore, the rationale for the treatment of PD with the rotigotine transdermal patch is discussed, focusing in particular on the related sleep disorders.

AB - Rotigotine (Neupro®) is a non-ergolinic dopamine agonist available as a transdermal patch that can be applied once daily. To date, it is approved as monotherapy for the treatment of early Parkinson's disease (PD), and as adjunctive therapy to levodopa in the treatment of PD, including the advanced stage of the disease, when the efficacy of levodopa is reduced or becomes inconsistent and there are .uctuations in the therapeutic effect (end-dose, 'ON-OFF' phenomenon). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption is not needed, constant drug delivery, and ease of use. This review provides an overview of several aspects of the use of the rotigotine transdermal patch, including the important issue of the management of sleep disorders in advanced PD patients, as well as the chemistry, preclinical and clinical pharmacology, efficacy, safety and tolerability of the drug. Furthermore, the rationale for the treatment of PD with the rotigotine transdermal patch is discussed, focusing in particular on the related sleep disorders.

KW - Parkinson's disease

KW - Quality of life

KW - Rotigotine

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=77954897327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954897327&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 21

EP - 25

JO - Functional Neurology

JF - Functional Neurology

SN - 0393-5264

IS - 1

ER -